NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/07/2026 14:40
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization1,467.67 mln
Float303 mln
Earnings Date05/20/2026
Piotroski F-Score
4
/ 9
Borderline
Beneish M-Score
7.92
Highly suspicious
1-Year Forecast
14.00
Transformational upside
Relative Strength
6
/ 100
Severely lagging
Debt / Equity
0.01
Debt-free
ROE
-416
Deeply negative
Business Description
AtaiBeckley Inc. is a New York-based company founded in 2018 that works to develop new treatments for mental health conditions, operating across the United States, Germany, and Canada. The company focuses on a broad range of experimental medicines targeting conditions such as depression, anxiety, schizophrenia, and alcohol use disorder, with several drugs currently in clinical trials. Many of its treatments are based on psychedelic or psychedelic-inspired compounds, reflecting a growing scientific interest in this area of medicine.
